Join to view full profile
1001 Calumet AveDyer, IN 46311
Phone+1 219-924-8178
Dr. Shah is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Neel Shah, based in Dyer, IN, specializes in Oncology with a focus on conditions such as amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma. His education includes a fellowship in Hematology and Medical Oncology at Rush University Medical Center and a residency in Internal Medicine at the University of Illinois College of Medicine at Chicago. Dr. Shah is an accomplished author with publications on predicting responses to immune checkpoint inhibitors and their resistance in cancer patients, which have been cited numerous times. He has received certifications for CMS Meaningful Use Stages 1 and 2 through various healthcare technology platforms.
Education & Training
McGaw Medical Center of Northwestern UniversityResidency, Gastroenterology, 2020 - 2026
Rush University Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2004 - 2007
Wayne State University School of MedicineClass of 2004
Certifications & Licensure
IN State Medical License 2014 - 2027
FL State Medical License 2014 - 2021
IL State Medical License 2006 - 2017
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification GeniusDoc EHR, GeniusDoc, Inc., 2013-2015, 2017
- CMS Meaningful Use Stage 2 Certification GeniusDoc, GeniusDoc, Inc., 2013-2015, 2017
- CMS Meaningful Use Stage 2 Certification iKnowMed Generation 2, McKesson, 2013-2015, 2017
Publications & Presentations
PubMed
- 76 citationsProliferative potential and resistance to immune checkpoint blockade in lung cancer patientsSarabjot Pabla, Jeffrey M. Conroy, Mary Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos
Journal for Immunotherapy of Cancer. 2019-02-01 - 70 citationsNext generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJeffrey M. Conroy, Sarabjot Pabla, Mary Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos
Journal for Immunotherapy of Cancer. 2019-01-24 - 121 citationsPredicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.Carl Morrison, Sarabjot Pabla, Jeffrey M. Conroy, Mary Nesline, Sean T. Glenn
Journal for Immunotherapy of Cancer. 2018-05-09
Other Languages
- Gujarati, Spanish
External Links
- MD Consultants, LLChttp://www.mdconsultants.info
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
